Treatment of pigs with PCV2 antigent
The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets.
1. A method for the prophylaxis of PCV2 infection in a pig in need thereof or for the reduction of clinical symptoms caused by or associated with a PCV2 infection in a pig in need thereof, wherein the pig has maternal anti-PCV2 antibodies and is 1 to 20 days of age, the method comprising the step of:
administering a single dose of an effective amount of a PCV2 ORF2 protein to a pig in need thereof, wherein the PCV2 ORF2 protein has at least 90% sequence homology with SEQ ID NO. 11 and wherein the prophylaxis of PCV2 infection or the reduction of clinical symptoms caused by or associated with a PCV2 infection occurs after the single dose of PCV2 ORF2 protein.
2. The method according to claim 1 , wherein the animals having anti-PCV-2 antibodies have an anti-PCV2 antibody titre of more than 1:100 in a PCV specific immunoassay.
3. The method according to claim 2 , wherein the animals have the anti-PCV2 antibody titre at the time the PCV2 antigen is administered.
4. The method according to claim 1 , wherein the animals having anti-PCV-2 antibodies have an anti-PCV2 antibody titre of more than 1:1000 in a PCV specific immunoassay.
5. The method according to claim 1 , wherein the PCV2 ORF2 protein is administered at day 7 of age or later.
6. The method according to claim 1 , wherein the PCV-2 ORF2 protein is administered at day 14 of age or later.
7. The method according to claim 1 , wherein the treatment or prophylaxis results in shortening of the viremia phase of 5 or more days as compared to pigs of a non-treated control group.
8. The method according to claim 1 , wherein the PCV-2 ORF2 protein is expressed by a recombinant baculovirus prior to administration.
9. The method according to claim 1 , wherein the PCV2 ORF2 protein is Ingelvac® CircoFLEX®.
10. The method according to claim 1 , wherein 0.5 to 18 μg/dose of said PCV2 ORF2 protein is administered to the pig in need of such treatment.
11. The method according to claim 1 , wherein the prophylaxis of PCV2 infection results in an improvement in comparison to animals of a non-treated control group in a vaccine efficacy parameter selected from the group consisting of a reduction in the loss of weight gain, a shorter duration of viremia, an earlier end to viremia, a lower virus load, or combinations thereof.
12. A method for the prophylaxis of a PCV2 infection or for the reduction of clinical symptoms caused by PCV2 infection of piglets between 1 and 20 days of age that are PCV2 maternally derived antibody positive against PCV2 infection, comprising administering a single dose of a vaccine composition comprising at least 0.2 μg PCV2 ORF2 protein to a piglet in need thereof wherein the prophylaxis of PCV2 infection or the reduction of clinical symptoms caused by or associated with a PCV2 infection occurs after the single dose of PCV2 ORF2 protein.
13. The method of claim 12 , wherein the amount of PCV2 ORF2 protein is 0.5 μg to 18 μg.
14. The method of claim 12 , wherein the vaccine composition is effective for the protection of the piglets after a single dose thereof.
15. A method for the prophylaxis of PCV2 infection in a pig in need thereof or for the reduction of clinical symptoms caused by or associated with a PCV2 infection in a pig in need thereof, wherein the pig has anti-PCV2 maternal antibodies and is 1 to 20 days of age, the method comprising the step of:
administering a single dose of 0.5 to 18 μg/dose of PCV2 ORF2 protein to a pig in need thereof, wherein the PCV2 ORF2 protein has at least 90% sequence homology with SEQ ID NO. 11 and wherein the prophylaxis of PCV2 infection or the reduction of clinical symptoms caused by or associated with a PCV2 infection occurs after the single dose of PCV2 ORF2 protein.